Woodline Partners LP Purchases 12,334 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Woodline Partners LP raised its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 2.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 537,428 shares of the company's stock after buying an additional 12,334 shares during the period. Woodline Partners LP owned 0.83% of Kymera Therapeutics worth $21,621,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in KYMR. Blue Trust Inc. increased its position in shares of Kymera Therapeutics by 74.8% in the fourth quarter. Blue Trust Inc. now owns 631 shares of the company's stock valued at $25,000 after acquiring an additional 270 shares during the last quarter. State of Wyoming bought a new position in Kymera Therapeutics in the fourth quarter valued at approximately $45,000. KBC Group NV grew its stake in Kymera Therapeutics by 53.8% in the fourth quarter. KBC Group NV now owns 2,151 shares of the company's stock valued at $87,000 after purchasing an additional 752 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Kymera Therapeutics by 95.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,812 shares of the company's stock worth $194,000 after purchasing an additional 2,350 shares during the last quarter. Finally, Summit Investment Advisors Inc. raised its stake in shares of Kymera Therapeutics by 9.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock worth $198,000 after purchasing an additional 406 shares in the last quarter.

Analyst Ratings Changes

KYMR has been the subject of several analyst reports. UBS Group decreased their target price on shares of Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Bank of America decreased their price objective on shares of Kymera Therapeutics from $47.00 to $44.00 and set a "neutral" rating for the company in a research report on Monday, May 12th. Wall Street Zen raised shares of Kymera Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday. Citigroup began coverage on Kymera Therapeutics in a report on Thursday, March 13th. They set a "buy" rating and a $52.00 price target for the company. Finally, HC Wainwright boosted their price target on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Five analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Kymera Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $55.25.

Kymera Therapeutics Price Performance

NASDAQ KYMR traded down $0.68 during trading hours on Monday, reaching $29.49. The company's stock had a trading volume of 352,793 shares, compared to its average volume of 562,279. The firm has a fifty day simple moving average of $28.96 and a 200-day simple moving average of $36.29. Kymera Therapeutics, Inc. has a 52 week low of $19.45 and a 52 week high of $53.27. The stock has a market cap of $1.92 billion, a P/E ratio of -12.60 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Friday, May 9th. The company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($0.92) by $0.10. The company had revenue of $22.10 million for the quarter, compared to analyst estimates of $11.38 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. Kymera Therapeutics's revenue was up 114.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.69) earnings per share. On average, research analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Insiders Place Their Bets

In other Kymera Therapeutics news, COO Jeremy G. Chadwick sold 1,383 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the completion of the sale, the chief operating officer now directly owns 67,800 shares in the company, valued at approximately $2,064,510. This trade represents a 2.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Bruce N. Jacobs sold 7,035 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the sale, the chief financial officer now owns 201,886 shares in the company, valued at approximately $6,147,428.70. The trade was a 3.37% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,659 shares of company stock valued at $324,567. 16.01% of the stock is currently owned by company insiders.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.